Project Details
Description
Species specific optimization and development of rifamycins for the treatment of nontuberculous mycobacterial lung disease
| Status | Active |
|---|---|
| Effective start/end date | 6/6/23 → 5/31/24 |
Funding
- HACKENSACK MERIDIAN HEALTH, INC
- NATIONAL INSTITUTES OF HEALTH (NIH)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.